Pegfilgrastim

🧮 Dose calculator

Febrile neutropenia (empiric therapy) · Regimen source: FDA Neulasta · 2.1

• • Once per chemotherapy cycle; not between 14 days before and 24 hours after chemotherapy. FDA Neulasta · 2.1
• • Haematopoietic acute radiation syndrome: two 6 mg doses one week apart. FDA Neulasta · 2.2

Enter age and weight.

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Neulasta · 8.1

  “Risk Summary Although available data with Neulasta use in pregnant women are insufficient to establish whether there is a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes, there are available data from published studies in pregnant women exposed to filgrastim products.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Neulasta · 8.2

  “Risk Summary There are no data on the presence of pegfilgrastim in human milk, the effects on the breastfed child, or the effects on milk production.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Neulasta · 8.4

  “The safety and effectiveness of Neulasta for chemotherapy-induced neutropenia and hematopoietic subsyndrome of acute radiation syndrome have been established in pediatric patients.”

• 👴 Older adultsNo specific problem stated

  Label: no specific difference or dose adjustment stated for older adults. FDA Neulasta · 8.5

  “No overall differences in safety or effectiveness were observed between patients aged 65 and older and younger patients.”

• ⚥ Females & males of reproductive potentialNo data

  The source for this drug has no section for this group.